BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2017

View Archived Issues

Alyeyuba shows good preclinical results for the treatment of cutaneous leishmaniasis

Read More

Zafgen begins phase II study of ZGN-1061 in type 2 diabetes

Read More

Novel approach to develop tools for detection and monitoring of multiple neurodegenerative diseases

Read More

VAXIMM's oral T-cell immunotherapy granted orphan drug status in E.U.

Read More

Umecrine Cognition reports favorable results from phase Ib trial of GR-3027

Read More

Lef1 regulates hypothalamic neurogenesis and mediates anxiety in a wide variety of animal species

Read More

NIAID agrees to support phase I study of Geom Therapeutics' GT-1

Read More

Merger between Inspyr Therapeutics and Lewis and Clark Pharmaceuticals completed

Read More

First patient with DMD completes 15 months of treatment in Carmeseal-MD expanded access program

Read More

Preliminary phase I study of the third-generation EGFR inhibitor TAS-121 in NSCLC patients

Read More

First patient dosed in phase Ia study of OncoMed Pharmaceuticals' GITRL-Fc

Read More

Otonomy announces financial and business update

Read More

ND-L02-s0201 demonstrates efficacy in preclinical lung fibrosis models

Read More

FDA accepts for review the NDAs for binimetinib and encorafenib combination

Read More

Phase III ESSENCE study of SD-101 in epidermolysis bullosa does not meet primary endpoint

Read More

FDA grants orphan drug designation to Reata's omaveloxolone for malignant melanoma

Read More

Novel small conductance channel blockers presented by Acesion Pharma

Read More

FDA advisory committee recommends approval of Shingrix

Read More

AgeneBio wins grant to support GABA-A program for MCI due to Alzheimer's

Read More

Vanda reports phase II data on tradipitant in atopic dermatitis

Read More

Phase I results presented for resminostat/S-1 combination in pancreatic and biliary tract cancer

Read More

Alligator Bioscience enters 4-1BB research agreement with University of Navarra

Read More

FDA accepts for review sNDA for mirabegron in combination with solifenacin for overactive bladder

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing